PMID- 33832093
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 14
DP  - 2021 Apr 9
TI  - Immune-related adverse events with immune checkpoint inhibitors: Special 
      reference to the effects on the lungs.
PG  - e25275
LID - 10.1097/MD.0000000000025275 [doi]
LID - e25275
AB  - Immune checkpoint inhibitors (ICIs) have emerged as evolutionary treatments for 
      malignant diseases. Although ICIs can cause immune-related adverse events (irAEs) 
      in various organs, precise timing after ICI initiation has been scarcely 
      reported. Elucidating the effects of irAEs, such as time to onset, involvement of 
      major organs, influence on progression-free survival (PFS), and overall survival 
      (OS), are critical issues for physicians. Furthermore, lung-irAE as a whole is 
      not well known.We conducted a retrospective study of 156 patients who were 
      treated with ICIs and compared 82 irAE patients with 74 non-irAE patients.This 
      study clearly demonstrated that the preferred period after induction of ICIs was 
      significantly longer in lung-irAE than in other major organs (skin, digestive 
      tract, and endocrine). The effect of irAEs on PFS and OS was evident PFS in the 
      irAE group (n = 82) (median 128 days, interquartile range [IQR] 62-269 days, 
      P = .002) was significantly longer than that in the non-irAE group (n = 74) 
      (median 53 days, IQR 33-151 days). Similarly, OS was significantly longer in the 
      irAE group (median 578 days, IQR 274-1027 days, P = .007) than in the non-irAE 
      group (median 464 days, IQR: 209-842 days). However, this positive effect of 
      irAEs in the lungs was not proportional to the extent of severity.Lung-irAEs can 
      occur at a later phase than non-lung-irAEs and seemed not to prolong OS and PFS. 
      However, further studies are needed to support these findings.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Hirata, Aya
AU  - Hirata A
AD  - Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, 
      Japan.
FAU - Saraya, Takeshi
AU  - Saraya T
AUID- ORCID: 0000-0003-0502-8128
FAU - Kobayashi, Fumi
AU  - Kobayashi F
FAU - Noda, Akinari
AU  - Noda A
FAU - Aso, Kaori
AU  - Aso K
FAU - Sakuma, Sho
AU  - Sakuma S
FAU - Kurokawa, Nozomi
AU  - Kurokawa N
FAU - Inoue, Manami
AU  - Inoue M
FAU - Mikura, Sunao
AU  - Mikura S
FAU - Oda, Miku
AU  - Oda M
FAU - Ishida, Manabu
AU  - Ishida M
FAU - Honda, Kojiro
AU  - Honda K
FAU - Nakamoto, Keitaro
AU  - Nakamoto K
FAU - Tamura, Masaki
AU  - Tamura M
FAU - Takata, Saori
AU  - Takata S
FAU - Ishii, Haruyuki
AU  - Ishii H
FAU - Takizawa, Hajime
AU  - Takizawa H
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Aged
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/administration & dosage/*adverse effects
MH  - Lung/*drug effects/immunology
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Time Factors
PMC - PMC8036099
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/04/10 06:00
MHDA- 2021/04/20 06:00
PMCR- 2021/04/09
CRDT- 2021/04/09 01:00
PHST- 2020/06/18 00:00 [received]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/04/09 01:00 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2021/04/09 00:00 [pmc-release]
AID - 00005792-202104090-00037 [pii]
AID - MD-D-20-05858 [pii]
AID - 10.1097/MD.0000000000025275 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Apr 9;100(14):e25275. doi: 
      10.1097/MD.0000000000025275.